> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# EUA for Gohibic for Some Hospitalized Covid Patients
- URL: https://www.fdaweb.com/eua-for-gohibic-for-some-hospitalized-covid-patients/
- Published: 2023-04-04T12:00:00.000Z
- Updated: 2026-09-14T18:23:40.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154134

FDA has approved an emergency use authorization (EUA) to use InflaRx’s Gohibic (vilobelimab) injection to treat Covid-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation or extracorporeal membrane oxygenation. An agency [statement](https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-gohibic-vilobelimab-injection-treatment-covid-19?utm%5Fmedium=email&utm%5Fsource=govdelivery) says the treatment targets a part of the immune system that is thought to play a role in the inflammation that leads to Covid-19 disease progression. FDA says the clinical trial supporting the EUA showed that patients treated with Gohibic had a lower risk of death by day 28 and day 60 of treatment compared to placebo.

The recommended Gohibic dosage is 800 mg administered by intravenous infusion after dilution, given up to six times over the treatment period, FDA says. The most common adverse reactions with using Gohibic are pneumonia, sepsis, delirium, pulmonary embolism, hypertension, pneumothorax, deep vein thrombosis, herpes simplex, enterococcal infection, bronchopulmonary aspergillosis, hepatic enzyme increase, urinary tract infection, hypoxia, thrombocytopenia, pneumomediastinum, respiratory tract infection, supraventricular tachycardia, constipation, and rash. Serious infections due to bacterial, fungal, or viral pathogens have been reported in patients with COVID-19 receiving Gohibic, according to the statement.